Recursion Pharmaceuticals, Inc.

BMV:RXRX * Stock Report

Market Cap: Mex$33.1b

Recursion Pharmaceuticals Management

Management criteria checks 2/4

Recursion Pharmaceuticals' CEO is Chris Gibson, appointed in Nov 2013, has a tenure of 11.5 years. total yearly compensation is $8.50M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 1.72% of the company’s shares, worth MX$570.64M. The average tenure of the management team and the board of directors is 0.8 years and 10.7 years respectively.

Key information

Chris Gibson

Chief executive officer

US$8.5m

Total compensation

CEO salary percentage7.1%
CEO tenure11.5yrs
CEO ownership1.7%
Management average tenureless than a year
Board average tenure10.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Gibson's remuneration changed compared to Recursion Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$575m

Dec 31 2024US$8mUS$600k

-US$464m

Sep 30 2024n/an/a

-US$378m

Jun 30 2024n/an/a

-US$375m

Mar 31 2024n/an/a

-US$354m

Dec 31 2023US$9mUS$561k

-US$328m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$260m

Mar 31 2023n/an/a

-US$249m

Dec 31 2022US$6mUS$498k

-US$239m

Sep 30 2022n/an/a

-US$247m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$212m

Dec 31 2021US$674kUS$485k

-US$186m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$124m

Mar 31 2021n/an/a

-US$99m

Dec 31 2020US$3mUS$270k

-US$87m

Compensation vs Market: Chris's total compensation ($USD8.50M) is above average for companies of similar size in the MX market ($USD678.22K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Gibson (41 yo)

11.5yrs

Tenure

US$8,499,586

Compensation

Dr. Christopher C. Gibson, Ph.D. also known as Chris, serves as Member of Board at Altitude Lab. He is Director of Cellino Biotech, Inc. from October 2024. Dr. Gibson is a Co-Founder of Recursion Pharmaceu...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Gibson
Co-Founder11.5yrsUS$8.50m1.72%
MX$ 570.6m
Ben Taylor
CFO & President of Recursion UKless than a yearUS$8.59m0.036%
MX$ 12.0m
David Mauro
Chief Medical Officer1.9yrsUS$1.93m0.013%
MX$ 4.4m
Najat Khan
Chief R&D Officerless than a yearUS$9.19m0.0013%
MX$ 437.6k
Kristen Rushton
Chief Operating Officerless than a yearno datano data
Kevin Leggat
Vice President of Finance & Accountingno datano datano data
Benjamin Mabey
Chief Technology Officer5.3yrsno datano data
David Hallett
Chief Scientific Officerless than a yearno datano data
Nathan Hatfield
Chief Legal Officer & General Counsel1.6yrsno datano data
Erica Fox
Chief People and Impact Officerless than a yearno datano data
Matthew Kinn
Chief Business Officerless than a yearno datano data
Imran Haque
Senior Vice President of AI & Digital Sciences1.8yrsno datano data

0.8yrs

Average Tenure

44yo

Average Age

Experienced Management: RXRX *'s management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Christopher Gibson
Co-Founder11.5yrsUS$8.50m1.72%
MX$ 570.6m
Najat Khan
Chief R&D Officer1.1yrsUS$9.19m0.0013%
MX$ 437.6k
Robert Lollini
Member of Business Advisory Panel10.5yrsno datano data
H. Fell
Member of Business Advisory Panel10.9yrsno datano data
Joseph Miletich
Chairman of Therapeutics Advisory Board3.8yrsno datano data
Robert Hershberg
Independent Chairman5.2yrsUS$316.48k0.0096%
MX$ 3.2m
Dean Li
Independent Director11.5yrsUS$296.73k0.79%
MX$ 262.0m
Blake Borgeson
Independent Director12.3yrsUS$294.98k1.75%
MX$ 581.3m
Anne Carpenter
Member of Scientific and Technical Advisory Board11.1yrsno datano data
Kirk Thomas
Member of Scientific & Technical Advisory Board11.1yrsno datano data
Zavain Dar
Independent Director8.7yrsUS$304.23k0.024%
MX$ 8.1m
Elaine Sun
Independent Directorless than a yearno datano data

10.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: RXRX *'s board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 15:22
End of Day Share Price 2025/05/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gal MundaBerenberg
Gaurav GoparajuBerenberg
Alec StranahanBofA Global Research